Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?
Hohenberger
Peter
P
epartment of Surgery, Faculty of Medicine, University of Heidelberg, Mannheim, Germany. peter.hohenberger@chir.ma.uni-heidelberg.de
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D017024:Chemotherapy, Adjuvant; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate